Background/Aims: Lipoproteins have been reported to be associated with prognosis in various cancers; however, the prognostic value of lipoproteins in patients with nasopharyngeal carcinoma (NPC) remains largely unknown. We aim to asses the role of circulating lipoproteins in locoregionally advanced NPC patients. Methods: Between October 2009 and August 2012, a total of 1,081 patients with stage III-IVB NPC were included in the analysis. Circulating highdensity lipoprotein (HDL) and low-density lipoprotein (LDL) are the two key lipoproteins, which were measured at baseline. Receiver operating characteristic (ROC) curve analysis was used to evaluate different cut-off points for lipoproteins. Actuarial rates were performed using Kaplan-Meier methods and the log-rank test. Results: The cutoff points of HDL, LDL, and LDL/HDL ratio were 1.17 mmol/L, 3.75 mmol/L, and 2.73, respectively. At 5 years, high HDL (>1.17 mmol/L) was significantly associated with better overall survival (OS, 86.6% vs. 78.9%; P=0.004), distant metastasis-free survival (DMFS, 86.9% vs. 80.8%; P=0.004), locoregional relapse-free survival (LRFS, 90.8% vs. 85.4%; P=0.010), and progression-free survival (PFS, 79.1% vs. 70.2%; P= 0.001) than low HDL (≤1.17 mmol/L). In contrast, high LDL (>3.75 mmol/L) tend to be inferior OS (79.1% vs. 84.9%; P= 0.016) in compassion with low LDL (≤3.75 mmol/L). Likewise, patients with high LDL/HDL ratio (>2.73) tend to be inferior OS (79.3% vs. 86.9%; P=0.001), DMFS (81.9% vs. 86.5%; P=0.030), and PFS (72.6% vs. 77.8%; P= 0.034) than those of low LDL/HDL ratio (≤2.73). In multivariate analysis, baseline HDL was found to be a significant prognostic factor for LRFS (HR= 0.65; 95% CI, 0.45-0.93; P= 0.019) and PFS (HR=0.75; 95% CI,
Introduction
Previous studies have reported that nasopharyngeal carcinoma (NPC) is a highly prevalent malignancy in Southern China, with the annual incidence rate between 15 and 50 cases per 100, 000 persons [1] . Currently, the Tumor-Node-Metastasis (TNM) stage is mainly used to predict NPC prognosis. However, prediction of NPC patients survival still remains challenging within current TNM staging system, and patients in the same TNM stage often undergo substantial clinical heterogeneity [2] . To date, plasma Epstein-Barr viral (EBV) DNA titre remains the only biomarker with clinical utility in NPC [3, 4] . However, the high cost and the large interlaboratory variability of examination of EBV DNA enables the difficulty to apply in routine clinical practice [5] . Thus, it is of great interest to screen some inexpensive, objective, and easily detected markers to complement the TNM staging system in prognostication of NPC.
Lipoprotein plays an important role in cellular structure, as well as a precursor to several biochemical pathways [6, 7] . The two key lipoproteins are high-density lipoprotein (HDL) and low-density lipoprotein (LDL). Several studies have reported a significant inverse relation between lipoproteins and the risk of cancer at multiple sites [8] [9] [10] . Furthermore, recent studies have demonstrated that HDL was a favorable prognostic marker in several cancers, including cancers of the lung, breast and stomach [11] [12] [13] [14] . Studies have also suggested that LDL enhances the colorectal cancer progression via reactive oxygen species (ROS) and the mitogen-activated protein kinase (MAPK) pathway [13] . For this reason, a question arises whether lipoprotein is associated with survival among patients with established NPC. However, limited studies have examined lipoprotein effects on the prognosis of NPC.
On the basis of this premise, we conducted a retrospective study to gain insight into long-term prognostic impact of lipoprotein on the outcome of patients with NPC, and explore the association between lipoproteins and clinical features from a large sample population.
Materials and Methods

Ethics statement
This study was conducted in compliance with institutional policy to protect patients' private information, and was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit (RDD) public platform, with the approval RDD number as RDDA2017000333.
Study patients
Patients were included if the following criteria were simultaneously satisfied: (1) 
Treatment and follow-up
All patients were treated according to the principle of treatment for NPC at our center. The prescribed doses of radiotherapy and chemotherapeutic regimens were the same as that described previously [16] . Our primary endpoint was overall survival (OS), and our secondary endpoints were distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRFS), and progression-free survival (PFS). Patients during the first 2 years were seen every three months, years 3-5 every six months, and annually thereafter until death. The duration of follow-up was calculated from the first day of therapy to either the day of death or the day of the last examination.
Statistical analysis
Receiver operating characteristic (ROC) curve analysis was used to evaluate different cut-off points for lipoprotein. The area under the ROC curve was used to assess the predicted validity of lipoprotein, based on the method of Hanley and McNeil [17, 18] . The χ² test was used to evaluate the association of lipoproteins with tumor stage. Actuarial rates were performed using Kaplan-Meier methods and the log-rank test. Multivariate analyses were performed using the Cox proportional hazards model to test the independent significance of different factors. All tests were twosided, and we deemed P values of less than 0.05 to be significant. All statistical analyses were completed with R 3.1.2.
Results
Patient characteristics
Between October 2009 and August 2012, a total of 1081 patients with NPC who fulfilled the inclusion criteria were included. The characteristics of the 1081 patients were presented in Table 1 . Among the 1081 patients, the median HDL was 1.27 mmol/L (Interquartile range (IQR): 1.07-1.55 mmol/L), the median LDL was 3.25 mmol/L (IQR: 2.73-3.84 mmol/L), and the median LDL/HDL ratio was 2.66 (IQR: 2.12-3.38). The male to female ratio was 3.2:1 (826 men and 255 women), and the median age was 45 years (IQR: 37-53 years). By TNM stage, 662 (61.2%) patients were at stage III and 419 (38.8%) at stage IVA-B. Concurrent chemoradiotherapy (CCRT) alone was delivered to 471 patients (43.6%), and neoadjuvant chemotherapy (NACT) plus concurrent chemoradiotherapy was delivered to 610 patients (56.4%). The median follow-up for the entire cohort was 63.6 months (range: 1.2-86 months), and the 5-year survival rates for all patients were as follows: OS, 83.1%; DMFS, 84.5%; LRFS, 89.0%; and PFS, 75.1%. 
The prognostic value of lipoproteins
The cut-off values for the HDL, LDL, and LDL/HDL ratio were 1.17 mmol/L, 3.75 mmol/L and 2.73, respectively, as determined by ROC curves. Based on optimal cutoff points, each biomarker was dichotomized into the high and low groups. At 5 years, high HDL was robustly associated with an improvement of OS (86.6% vs 78.9%; P= 0.004) (Fig. 1A) , DMFS (86.9% vs 80.8%; P=0.004) (Fig.  1B) , LRFS (90.8% vs 85.4%; P= 0.010) (Fig. 1C) , and PFS (79.1% vs 70.2%; P= 0.001) (Fig. 1D) Fig. 3C ). However, the 5-year OS (79.3% vs. 86.9%; P=0.001) (Fig. 3A) , DMFS (81.9% vs. 86.5%; P=0.030) (Fig. 3B) and PFS (72.6% vs. 77.8%; P= 0.034) (Fig. 3D) for patients with high HDL were all significantly inferior compared to patients with low HDL.
Multivariate analysis was performed to further adjust for age, gender, T stage, N stage, family history, smoking history, chemotherapy, HDL, LDL, and LDL/HDL ; P < 0.001) was independent prognostic factors for DMFS (Table 2) .
Correlation between HDL and clinicopathological characteristics
In this study, ROC curve was used to evaluate different cut-off points for circulating lipoprotein. As described above, patients were divided into two groups according to HDL: high HDL (> 1.17 mmol/L) and low HDL (≤ 1.17 mmol/L). The correlations between circulating HDL and various clinicopathological features were examined (Table 3 ). Female patients generally had high HDL. In contrast, smokers, advanced N stage (N2/3), and stage IVA-B were more likely to present low HDL. However, no significant differences were found between two groups regarding age, T stage, family history, or chemotherapy (P > 0.05 for all; Table 3 ). Table 2 . Multivariate analysis of HDL, LDL, and LDL/HDL ratio determined by ROC for patients with locoregionally advanced NPC. Abbreviation: OS, overall survival; DMFS, distant metastasis-free survival; LRFS, locoregional relapse-free survival; PFS, progression-free survival; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LDL/ HDL ratio, low-density-to-high-density lipoprotein ratio; HR, rate ratio; CI, confidence interval 
Discussion
According to previous studies, the prognosis of patients with NPC is far from clearly defined [2] . In the current study, we sought to determine the prognostic value of pretreatment lipoproteins in patients with locoregionally advanced NPC. Our analysis on a large sample size provided a quantitative assessment of the impact of baseline lipoproteins on the survival of locoregionally advanced NPC patients. Our findings from the present study was that circulating lipoprotein is potentially an ideal prognostic factor in patients with NPC. Serum HDL measurements will be of great clinical significance in the management of NPC.
It is well known that HDL acts as a supplier of cholesterol to tumor cells by removing excess cholesterol from peripheral tissues [19] . Several studies [11] [12] [13] have reported a significant inverse relation between HDL and disease prognosis at many sites. As shown in a study by Chi et al [11] ., high HDL was an independent prognostic factor of PFS in lung adenocarcinoma patients. Another study by Wolfe et al [14] . indicated that low HDL was associated with poor OS in breast cancer patients. As an extension in the current study, high HDL was significantly associated with an improvement in the LRFS and PFS of locoregionally advanced NPC. We consider that HDL measurements will be of great clinical importance in the management of NPC, especially, when considering "decision points" in treatment algorithms.
However, Liu et al [20] . analyzed the effect of circulating HDL in NPC patients, suggesting that high HDL was an independent adverse prognostic factor in patients with NPC. There are two possible reasons for this discrepancy. One may be explained by the treatment heterogeneity from the study, since they did not account for the influence of treatment modality in their study, which might partly affect the clinical outcomes. In contrast, only patients with locoregionally advanced NPC treated with concurrent chemoradiotherapy with or without NACT were eligible for this study, which may improve the homogeneity of study group. Another possible reason is that the method of measurement in lipoprotein may partly account for the conflicting findings between Liu et al.'s study and the present study. In the study of Liu et al, majority of patients were diagnosed before 2005, and circulating HDL was measured using the antibody block method. However, with recent advances in measurement technology, fasting blood samples by standard tests were used to measure circulating HDL in the current study.
Previous studies have confirmed that circulating LDL was associated with atherosclerosis [21] . However, there remains a relative paucity of data examining the influence of circulating LDL on survival in patients with NPC. To date, only one study [22] was available for the prognostic value of serum LDL in NPC, which found that elevated LDL was associated with inferior OS. The current study also confirmed consistent significant trends between LDL and OS among patients with locoregionally advanced NPC, but this association failed to retain significance after adjusting for TNM stage. It may suggest that LDL was not the primary factor responsible for the survival in patients with locoregionally advanced NPC. As an extension in this study, we further analyzed the prognostic power of survival for LDL/ HDL ratio. Although high LDL/HDL ratio was significantly associated with inferior OS, DMFS, and PFS by univariate analyses, this association was not significant after adjusting for TNM stage. It is plausible that LDL/HDL ratio contributes to patient stratification by adding a layer of information on disease burden, which could explain in part our inability to detect a prognostic value of LDL/HDL ratio in locoregionally advanced NPC.
The associations between circulating HDL and sex have been reported before. Freedman et al [23] . reported that men tended to have lower HDL than women, which may attribute to gonadal hormones acting together with direct or indirect contributions from other sex-specific factors [24] . Consistent with the study of Freedman et al, we also found that female patients more commonly present high HDL among locoregionally advanced NPC. The present study noted a decreased HDL in cigarette smokers compared to nonsmokers, which is generally consistent with findings reported in previous studies [25, 26] . An interesting finding of this study was that patients with advanced N stage or stage IVA-B more often had Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry low HDL. However, further investigation is required to explain the mechanism underlying this correlation between tumor stage and HDL in patients with NPC. In summary, our results demonstrate that circulating lipoprotein is potentially an ideal prognostic factor in patients with locoregionally advanced NPC. Compared with LDL and LDL/HDL ratio, HDL might be a more reliable predictor for treatment outcomes. Thus, we consider that serum HDL measurements will be of great clinical significance in the management of NPC.
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